AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35141484 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercises with neuromuscular inhibition (NMI) technique - 25 patients, 3 times per week for three weeks
Number of subjects: 50
Study 35141484 — intervention group
Group type: COMPARATOR
Intervention: Comparison between rESWT and NMI exercises
Number of subjects: 50
Study 35428697 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg monthly for ≤6 years
Number of subjects: 424
Study 33040356 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-severe COL4A5 variant group
Number of subjects: 60
Study 33040356 — intervention group
Group type: COMPARATOR
Intervention: Severe COL4A5 variant group
Number of subjects: 60
Study 35230415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 0
Study 35230415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35307033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus rosuvastatin 5 mg daily
Number of subjects: 70
Study 35307033 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 5 mg daily
Number of subjects: 70
Study 33837117 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI with average apparent diffusion coefficient (ADC) value and percentage of brain voxels with ADC <650 × 10‐6 mm2/s and <450 × 10‐6 mm2/s
Number of subjects: 79
Study 33837117 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including clinical characteristics, EEG, somatosensory evoked potentials (SSEP), and ADC value
Number of subjects: 79
Study 35285882 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft ultra-processed meal
Number of subjects: 50
Study 35285882 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft minimally processed meal
Number of subjects: 50
Study 35285882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard minimally processed meal
Number of subjects: 50
Study 35285882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard ultra-processed meal
Number of subjects: 50
Study 35285882 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy intake across the day
Number of subjects: 50
Study 34912072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Number of subjects: 172
Study 34912072 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (CER)
Number of subjects: 172
Study 33714585 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage containing Lactobacillus paracasei LC-37
Number of subjects: 0
Study 32782010 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/day thylakoid
Number of subjects: 48
Study 34653352 — intervention group
Group type: EXPERIMENTAL
Intervention: Belin ABCD Progression Display (BAPD)
Number of subjects: 155
Study 34653352 — intervention group
Group type: COMPARATOR
Intervention: Conventional metrics (minimum corneal thickness)
Number of subjects: 155
Study 34653352 — intervention group
Group type: COMPARATOR
Intervention: Conventional metrics (central corneal thickness)
Number of subjects: 155
Study 34653352 — intervention group
Group type: COMPARATOR
Intervention: Conventional metrics (maximum keratometry)
Number of subjects: 155
Study 34653352 — intervention group
Group type: COMPARATOR
Intervention: Conventional metrics (corneal astigmatism)
Number of subjects: 155
Study 34653352 — intervention group
Group type: COMPARATOR
Intervention: Conventional metrics (back mean keratometry)
Number of subjects: 155
Study 34653352 — intervention group
Group type: COMPARATOR
Intervention: Conventional metrics (front mean keratometry)
Number of subjects: 155
Study 32986105 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted gene testing (TGT) and tailored first-line therapy
Number of subjects: 0
Study 32986105 — intervention group
Group type: COMPARATOR
Intervention: Empirical imatinib therapy
Number of subjects: 0
Study 35058270 — intervention group
Group type: EXPERIMENTAL
Intervention: UPSIDES Proportionate Translation Methodology (SIS)
Number of subjects: 108
Study 32877521 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-taken samples from the rectum or pharynx
Number of subjects: 1793
Study 32877521 — intervention group
Group type: COMPARATOR
Intervention: Clinician-taken samples from the rectum or pharynx
Number of subjects: 1793
Study 35550194 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery balls plus warm showers (Group A)
Number of subjects: 105
Study 35550194 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery balls (Group B)
Number of subjects: 105
Study 35550194 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 105
Study 33150170 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing licochalcone A, 1,2‐decanediol, L‐carnitine, and salicylic acid applied twice a day for 12 weeks
Number of subjects: 110
Study 33150170 — intervention group
Group type: COMPARATOR
Intervention: Vehicle moisturizer applied twice a day for 12 weeks
Number of subjects: 110
Study 36423733 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) and CTO-PCI
Number of subjects: 0
Study 36423733 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) alone
Number of subjects: 0
Study 35776028 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-based total intravenous anesthesia (TIVA)
Number of subjects: 104
Study 35776028 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based inhalation anesthesia (SEVO)
Number of subjects: 104
Study 33724085 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic, bodyweight supported, treadmill-based training (n = 105)
Number of subjects: 200
Study 33724085 — intervention group
Group type: COMPARATOR
Intervention: Relaxation sessions (n = 95, control group)
Number of subjects: 200
Study 33724085 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 200
Study 34006498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus Pembrolizumab (Cohort A)
Number of subjects: 42
Study 34006498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus Pembrolizumab (Cohort B)
Number of subjects: 42
Study 34006498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus Pembrolizumab (Cohort C)
Number of subjects: 42
Study 34006498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (Cohort C)
Number of subjects: 42
Study 34006498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib monotherapy (Cohort C)
Number of subjects: 42
Study 34006498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus Pembrolizumab (Cohorts A and B)
Number of subjects: 42
Study 32703246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 900 mg daily for 6 months
Number of subjects: 0
Study 32703246 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 32703246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study 34117753 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern antiretroviral therapy (ART) regimens, specifically integrase inhibitor-based ART, with a median time to viral rebound of 22 days after treatment interruption.
Number of subjects: 45
Study 34117753 — intervention group
Group type: COMPARATOR
Intervention: Early-treated participants (ART initiated during early HIV infection)
Number of subjects: 45
Study 34117753 — intervention group
Group type: COMPARATOR
Intervention: Chronic-treated participants (ART initiated during chronic HIV infection)
Number of subjects: 45
Study 34117753 — intervention group
Group type: COMPARATOR
Intervention: Older protease inhibitor-based regimens (historic studies)
Number of subjects: 45
Study 33212138 — intervention group
Group type: EXPERIMENTAL
Intervention: Water consumption to the dictates of thirst (sated)
Number of subjects: 15
Study 33212138 — intervention group
Group type: COMPARATOR
Intervention: Salt water mouth rinses (thirst)
Number of subjects: 15
Study 32737097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble programme
Number of subjects: 0
Study 32737097 — intervention group
Group type: COMPARATOR
Intervention: Support as usual (Control)
Number of subjects: 0
Study 32116340 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious dermatoses, infestations, and papular urticaria (IDIP) observed in 505 (34.9%) persons; among them, 269 (53.3%) were males and 236 (46.7%) were females (X2=34.87, p=<0.001).
Number of subjects: 1447
Study 32116340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal dermatoses constituted more than 90% of the diseases, primarily due to pityriasis versicolor (430 cases, 79.6%).
Number of subjects: 1447
Study 32116340 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of pityriasis versicolor will significantly affect the prevalence of infectious dermatoses.
Number of subjects: 1447
Study 32790927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder youths
Number of subjects: 20
Study 32790927 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 20
Study 33100044 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 158
Study 33100044 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 158
Study 33100044 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (observational study)
Number of subjects: 158
Study 33100044 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperemia index
Number of subjects: 158
Study 33100044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Number of subjects: 158
Study 35236276 — intervention group
Group type: EXPERIMENTAL
Intervention: SEP-227900 (80 mg)
Number of subjects: 9
Study 32097541 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaria hypoxia (HH) at altitude levels of 3,000 m and 5,500 m
Number of subjects: 9
Study 32097541 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaria normoxia (HN)
Number of subjects: 9
Study 32097541 — intervention group
Group type: COMPARATOR
Intervention: Hypobaria conditions (HN and HH)
Number of subjects: 9
Study 32097541 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaria hypoxia (HH)
Number of subjects: 9
Study 34606378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg plus rituximab
Number of subjects: 150
Study 34606378 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 150
Study 33411187 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Mouth Breathing (IMB), N = 195
Number of subjects: 273
Study 33411187 — intervention group
Group type: COMPARATOR
Intervention: Persistent Mouth Breathing (PMB), N = 78
Number of subjects: 273
Study 35959845 — intervention group
Group type: EXPERIMENTAL
Intervention: SM DNA (530 mg day‐1)
Number of subjects: 50
Study 35959845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 50
Study 35959845 — intervention group
Group type: EXPERIMENTAL
Intervention: SM DNA (530 mg day‐1) in males
Number of subjects: 50
Study 35959845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin) in males
Number of subjects: 50
Study 35959845 — intervention group
Group type: EXPERIMENTAL
Intervention: SM DNA (530 mg day‐1) in females
Number of subjects: 50
Study 35959845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin) in females
Number of subjects: 50
Study 33905171 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person educational programme
Number of subjects: 180
Study 33905171 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media educational programme
Number of subjects: 180
Study 33905171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study 35395776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 μg/kg and maintenance dose of 0.5 μg/kg/h)
Number of subjects: 160
Study 35395776 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 160
Study 35395776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 160
Study 33040557 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics Clostridium butyricum
Number of subjects: 61
Study 33040557 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 32114466 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 60
Study 32114466 — intervention group
Group type: EXPERIMENTAL
Intervention: iACT
Number of subjects: 60
Study 32114466 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 60
Study 35399060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 1446
Study 35399060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1446
Study 34673939 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min of continuous priming taVNS before lexical training and testing each day
Number of subjects: 0
Study 34673939 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 msec of peristimulus taVNS preceding each to-be-learned item
Number of subjects: 0
Study 34673939 — intervention group
Group type: COMPARATOR
Intervention: Passive sham stimulation
Number of subjects: 0
Study 32282024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening program websites
Number of subjects: 162
Study 32282024 — intervention group
Group type: COMPARATOR
Intervention: Community medical centers
Number of subjects: 162
Study 35296973 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group 1 (EG-1)
Number of subjects: 105
Study 35296973 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group 2 (EG-2)
Number of subjects: 105
Study 35296973 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 105
Study 32507145 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping (KT) applied to the gastrocnemius muscle.
Number of subjects: 80
Study 32507145 — intervention group
Group type: COMPARATOR
Intervention: Stretching of the gastrocnemius muscle (60 seconds, repeated 4 times).
Number of subjects: 80
Study 36040612 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 37
Study 36040612 — intervention group
Group type: COMPARATOR
Intervention: Mannitol (placebo)
Number of subjects: 37
Study 34610730 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (12 weeks, jumps on nonconsecutive days)
Number of subjects: 41
Study 34610730 — intervention group
Group type: COMPARATOR
Intervention: Control (non-trained group)
Number of subjects: 41
Study 32240562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tag-7 gene-modified tumor cells-based vaccine (GMV), injected subcutaneously every 3 weeks until progression or for 2 years.
Number of subjects: 80
Study 32240562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tag-7 gene-modified tumor cells-based vaccine (GMV) in favorable prognosis (FP) group (MICA level ≤582 pg/mL, n = 15).
Number of subjects: 80
Study 32240562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tag-7 gene-modified tumor cells-based vaccine (GMV) in unfavorable prognosis (UF) group (MICA level >582 pg/mL, n = 12).
Number of subjects: 80
Study 32240562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tag-7 gene-modified tumor cells-based vaccine (GMV) in patients with stage III-IV MM with FP.
Number of subjects: 80
Study 32240562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tag-7 gene-modified tumor cells-based vaccine (GMV).
Number of subjects: 80
Study 616871147 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (quinapril, losartan, amlodipine, hydrochlorothiazide, bisoprolol) for 6 months
Number of subjects: 95
Study 616871147 — intervention group
Group type: COMPARATOR
Intervention: Control group (31 normotensives of the same age range)
Number of subjects: 95
Study 36197845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.Filo and MVA-BN-Filo vaccine regimens
Number of subjects: 72
Study 36197845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.Filo booster
Number of subjects: 72
Study 36197845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 34639299 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet (n = 23)
Number of subjects: 45
Study 34639299 — intervention group
Group type: COMPARATOR
Intervention: Meat-rich diet (n = 22)
Number of subjects: 45
Study 32560911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rotation training
Number of subjects: 94
Study 32560911 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 94
Study 33252629 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree family history of breast cancer in AA women
Number of subjects: 3244
Study 33252629 — intervention group
Group type: COMPARATOR
Intervention: First-degree family history of breast cancer in White women
Number of subjects: 3244
Study 33252629 — intervention group
Group type: EXPERIMENTAL
Intervention: All risk factors collectively in AA women
Number of subjects: 3244
Study 32459755 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 150
Study 32459755 — intervention group
Group type: COMPARATOR
Intervention: Secondary closure
Number of subjects: 150
Study 32459755 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap
Number of subjects: 150
Study 35549910 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for displaced wrist fractures
Number of subjects: 19
Study 35549910 — intervention group
Group type: COMPARATOR
Intervention: Cast without surgery for displaced wrist fractures
Number of subjects: 19
Study 32331084 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40mg
Number of subjects: 67
Study 32331084 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80mg to 40mg
Number of subjects: 67
Study 35477498 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-learning program (six modules)
Number of subjects: 0
Study 35477498 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during initial phase)
Number of subjects: 0
Study 34048358 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Relaxation-Based Virtual Reality (VR-GR)
Number of subjects: 51
Study 34848351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine administration of activated peripheral blood mononuclear cells (PBMC) at a dose of 1.106 cells on day 2 (D2) after stimulation with phytohemagglutinin (PHA) and human chorionic gonadotropin (hCG) for 48 hours.
Number of subjects: 213
Study 34848351 — intervention group
Group type: COMPARATOR
Intervention: Control group received sperm-washing medium.
Number of subjects: 213
Study 34848351 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC at D2 after hCG activation.
Number of subjects: 213
Study 32606319 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized genetic marker system using 14 novel STR loci identified from 64 samples.
Number of subjects: 64
Study 32606319 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diversity analysis in Chengdu Zoo population (n=25)
Number of subjects: 64
Study 32606319 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diversity analysis in Pingwu wild population (n=8)
Number of subjects: 64
Study 32606319 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual identification method using seven markers.
Number of subjects: 64
Study 32606319 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternity tests conducted on seven offspring with known mothers.
Number of subjects: 64
Study 32606319 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping database established for captive and wild populations.
Number of subjects: 64
Study 36436281 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS-v PLUS
Number of subjects: 51
Study 36436281 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS-v PLUS/ISA-51
Number of subjects: 51
Study 36436281 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS-v PLUS/Alhydrogel
Number of subjects: 51
Study 36436281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 34407805 — intervention group
Group type: EXPERIMENTAL
Intervention: Male involvement in family planning (FP) education
Number of subjects: 33
Study 34407805 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's education on FP
Number of subjects: 33
Study 34407805 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 32087143 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 mg fluocinolone acetonide insert
Number of subjects: 129
Study 32087143 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 129
Study 34010631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 6564
Study 34010631 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 6564
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral CT-positive/GC-negative test visits with extragenital testing
Number of subjects: 139718
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall positivity for GC
Number of subjects: 139718
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall positivity for CT
Number of subjects: 139718
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral positivity for GC
Number of subjects: 139718
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral positivity for CT
Number of subjects: 139718
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal positivity for GC
Number of subjects: 139718
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal positivity for CT
Number of subjects: 139718
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal positivity for GC
Number of subjects: 139718
Study 32187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal positivity for CT
Number of subjects: 139718
Study 34924394 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care plus makeup therapy (n = 18)
Number of subjects: 34
Study 34924394 — intervention group
Group type: COMPARATOR
Intervention: Skin care (control group, n = 16)
Number of subjects: 34
Study 34124246 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBand
Number of subjects: 30
Study 34124246 — intervention group
Group type: EXPERIMENTAL
Intervention: theratube
Number of subjects: 30
Study 34124246 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30